Both NF-κB and c-Jun/AP-1 involved in anti-β₂GPI/β₂GPI-induced tissue factor expression in monocytes

Summary

Our previous data has demonstrated that Toll-like receptor 4 (TLR4) and its signalling pathway can contribute to anti-β₂-glycoprotein I/β₂-glycoprotein I (anti-β₂GPI/β₂GPI) -induced tissue factor (TF) expression in human blood monocytes and acute monocytic leukaemia cell line THP-1. However, its downstream nuclear transcription factors have not been well explored. In the current study, we further investigated whether nuclear factor kappa B (NF-κB) and activator protein (AP-1) were activated and their roles in anti-β₂GPI/β₂GPI complex stimulating TF expression. The results showed that treatment of the cells with anti-β₂GPI (10 µg/ml)/β₂GPI (100 mg/ml) complex could markedly increase the levels of phosphorylated NF-κB (p-NF-κB p65) and c-Jun/AP-1 (p-c-Jun), as well as TF expression. Both NF-κB inhibitor PDTC (20 µM) and AP-1 inhibitor curcumin (25 mM) could attenuate TF expression induced by anti-β₂GPI/β₂GPI or APS-IgG/β₂GPI complex. Combination of any two inhibitors of MAPKs (SB203580/U0126 or SB203580/SP600125 or U0126/SP600125) could decrease activation of NF-κB. SB203580/SP600125 or U0126/SP600125, but not SB203580/U0126, could reduce the phosphorylation of c-Jun/AP-1. Neither NF-κB nor c-Jun/AP-1 activation caused by anti-β₂GPI/β₂GPI complex could be affected by TLR4 inhibitor TAK-242. In conclusion, our results indicate that both NF-κB and c-Jun/AP-1 can be activated and play important roles in the process of anti-β₂GPI/β₂GPI-induced TF expression in monocytes, thereby contributing to the pathological processes of antiphospholipid syndrome.

Keywords

Anti-β₂-glycoprotein I antibodies - β₂-glycoprotein I - NF-κB - AP-1 - tissue factor

• References

• 1 Mehdi AA, Uthman I, Khamashta M. Antiphospholipid syndrome: pathogenesis and a window of treatment opportunities in the future. Eur J Clin Invest 2010; 40: 451-464.
• 2 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 04: 295-306.
• 3 Allen KL, Fonseca FV, Betapudi V. et al. A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies. Blood 2012; 119: 884-893.
• 4 Arad A, Proulle V, Furie RA. et al. β2 glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood 2011; 117: 3453-3459.
• 5 Seshan SV, Franzke CW, Redecha P. et al. Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies. Blood 2009; 114: 1675-1683.
• 6 Nojima J, Masuda Y, Iwatani Y. et al. Tissue factor expression on monocytes induced by anti-phospholipid antibodies as a strong risk factor for thromboembolic complications in SLE patients. Biochem Biophys Res Commun 2008; 365: 195-200.
• 7 Zhou H, Wolberg AS, Roubey R. Characterisation of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004; 104: 2353-2358.
• 8 Ma K, Simantov R, Zhang JC. et al. High affinity binding of beta2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 2000; 275: 15541-15548.
• 9 Sorice M, Longo A, Capozzi A. et al. Anti-beta2-glycoproteinI antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007; 56: 2687-2697.
• 10 Raschi E, Borghi MO, Grossi C. et al. Toll-like receptors: another player in the pathogenesis of the antiphospholipid syndrome. Lupus 2008; 17: 937-942.
• 11 Alard JE, Gaillard F, Daridon C. et al. TLR2 is one of the endothelial receptors for beta 2-glycoprotein I. J Immunol 2010; 185: 1550-1557.
• 12 Lutters BC, Derksen RH, Tekelenburg WL. et al. Dimers of beta 2-glycoproteinI increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor2’. J Biol Chem 2003; 278: 33831-33838.
• 13 Zhang J, McCrae KR. Annexin A2 mediates endothelial cell activation by anti-phospholipid/anti-beta2 glycoprotein I antibodies. Blood 2005; 105: 1964-1949.
• 14 Romay-Penabad Z, Montiel-Manzano MG, Shilagard T. et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood 2009; 114: 3074-3083.
• 15 Hurst J, Lorenz M, Prinz N. et al. The role of toll-like receptors in the antiphosp-holipid syndrome. Curr Rheumatol Rep 2010; 12: 58-63.
• 16 Zhou H, Ling S, Yu Y. et al. Involvement of annexin A2 in anti-beta2GPI/ beta2GPI-induced tissue factor expression on monocytes. Cell Res 2007; 17: 737-739.
• 17 Zhou H, Wang H, Li N. et al. Annexin A2 mediates anti-beta2 GPI/beta2 GPI-induced tissue factor expression on monocytes. Int J Mol Med 2009; 24: 557-562.
• 18 Zhou H, Yan Y, Xu G. et al. Toll-like receptor (TLR)-4 mediates anti-β2GPI/β2 GPI-induced tissue factor expression in THP-1 cells. Clin Exp Immunol 2011; 163: 189-198.
• 19 Zhou H, Chen D, Xie H. et al. Activation of MAPKs in the anti-β2GPI/β2GPI-induced tissue factor expression through TLR4/IRAKs pathway in THP-1 cells. Thromb Res. 2012 epub ahead of print.
• 20 Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine 2008; 42: 145-151.
• 21 Xu G, Wen H, Zhou H. et al. Involvement of IRAKs and TRAFs in anti-β2GPI/β2GPI-induced tissue factor expression in THP-1 cells. Thromb Haemost 2011; 106: 1158-1169.
• 22 Allen KL, Hamik A, Jain MK. et al. Endothelial cell activation by antiphospholipid antibodies is modulated by Krüppel-like transcription factors. Blood 2011; 117: 6383-6391.
• 23 Vallabhapurapu S, Karin M. Regulation and Function of NF-κB Transcription Factors in the Immune System. Annu. Rev. Immunol 2009; 27: 693-733.
• 24 Wang S, Liu Z, Wang L. et al. NF-kappa B signalling pathway, inflammation and colorectal cancer. Cell Mol Immunol 2009; 06: 327-334.
• 25 Guo DL, Zhou H, Wu Y. et al. Involvement of ERK1/2/NF-κB signal transduction pathway in TF/FVIIa/PAR2-induced proliferation and migration of colon cancer cell SW620. Tumor Biol 2011; 32: 921-930.
• 26 Jiang JH, Slivova V, Jedinak A. et al. Gossypol inhibits growth, invasiveness, and angiogenesis in human prostate cancer cells by modulating NF-κB/AP-1 dependent- and independent-signalling. Exp Metastasis 2012; 29: 165-178.
• 27 Vaiopoulos AG, Papachroni KK, Papavassiliou AG. Colon carcinogenesis: Learning from NF-κB and AP-1. Int J Biochem Cell Biol 2010; 42: 1061-1065.
• 28 Xie H, Zhou H, Wang H. et al. Anti-β2GPI/β2GPI induced TF and TNF-α expression in monocytes involving both TLR4/MyD88 and TLR4/TRIF signalling pathways. Mol Immunol. 2012 epub ahead of print.
• 29 Willis R, Harris EN, Pierangeli SS. Pathogenesis of the antiphospholipid syndrome. Semin Thromb Hemost 2012; 38: 305-321.
• 30 Boles J, Mackman N. Role of tissue factor in thrombosis in antiphospholipid antibody syndrome. Lupus 2010; 19: 370-378.
• 31 Kornberg A, Blank M, Kaufman S. et al. Induction of tissue factor like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994; 153: 1328-1332.
• 32 Kornberg A, Renaudineau Y, Blank M. et al. Anti-beta2-glycoprotein I antibodies and anti-endothelial cell antibodies induce tissue factor in endothelial cells. IMAJ 2000; 02: 27-31.
• 33 Crowther MA, Ginsberg JS, Julian J. et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-1138.
• 34 López-Pedrera C, Buendía P, Cuadrado MJ. et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-κB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006; 54: 301-311.
• 35 Lambrianides A, Carroll CJ, Pierangeli SS. et al. Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signalling pathways. J Immunol 2010; 184: 6622-6628.
• 36 Mackman N. Regulation of the tissue factor gene. FASEB J 1995; 09: 883-889.
• 37 Fujioka S, Niu JG, Schmidt C. et al. NF-κB and AP-1 connection: mechanism of NF-κB-dependent regulation of AP-1 activity. Mol Cell Biol 2004; 24: 7806-7819.
• 38 Kawamoto T, Ii M, Kitazaki T. et al. TAK-242 selectively suppresses Toll-like receptor 4-signalling mediated by the intracellular domain. Eur J Pharmacol 2008; 584: 140-148.
• 39 Poulton K, Rahman A, Giles I. Examining how antiphospholipid antibodies activate intracellular signalling pathways: a systematic review. Semin Arthritis Rheum 2012; 41: 720-736.
• 40 Romay-Penabad Z, Aguilar-Valenzuela R, Urbanus RT. et al. Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome. Blood 2011; 117: 1408-1414.